Botulinum Toxin Type A 500 units Powder for solution for injection

DRUG4 trials

Sponsors

Ipsen Innovation, Centre Hospitalier Universitaire De Toulouse, Azienda Socio Sanitaria Territoriale Ovest Milanese

Conditions

Buerger's diseaseChronic migraineEpisodic MigraineLarge hernia widthand irreducible visceral content in the herniachronically retracted lateral abdominal wall muscles

Phase 2

Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease

Not yet recruitingCTIS2024-517772-38-00

Centre Hospitalier Universitaire De ToulouseBuerger's disease

Target: 8Updated: 2024-10-22

PROBHE: Prehabilitation with Botulinum Toxin A in complex hernia: an Italian prospective study on predictive scores of myofascial release.

Not yet recruitingCTIS2025-522451-25-00

Azienda Socio Sanitaria Territoriale Ovest Milaneseand irreducible visceral content in the hernia, chronically retracted lateral abdominal wall muscles, Large hernia width

Target: 1Updated: 2025-11-04

Phase 3

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants

Active, not recruitingCTIS2023-504839-40-00

Ipsen InnovationEpisodic Migraine

Start: 2024-03-18Target: 610Updated: 2025-04-28

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants

Active, not recruitingCTIS2023-504827-17-00

Ipsen InnovationChronic migraine

Start: 2024-03-18Target: 625Updated: 2025-10-16